Shareholders that lost money on Neumora Therapeutics, Inc. (NMRA) should contact The Gross Law Firm about pending Class Action - NMRA

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding its clinical trials and the efficacy of its flagship therapeutic candidate, Navacaprant [4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals or entities who purchased Neumora common stock during the class period starting on or about September 15, 2023 [3]. - The deadline for shareholders to register for the class action is April 7, 2025, and they are encouraged to register to monitor the case's progress [5]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [4]. - It is claimed that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [4]. Group 3: Legal Representation - The Gross Law Firm, a nationally recognized class action law firm, is representing the shareholders and aims to protect investors' rights against deceit and fraud [6]. - The firm emphasizes its commitment to ensuring responsible business practices and seeks recovery for investors who suffered losses due to misleading statements by companies [6].